Pricing Log in Create free account
Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue
+10.4%
EPS
−280.5%
Free cash flow
−60.4%
Total debt
+3.88%

Quarter to September 2026, against a year earlier

237.15 9.83 +4.32%
Market cap
$14.6B
P/E
62.6×
Fwd P/E
35.9×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Jazz Pharmaceuticals PLC (JAZZ) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Jazz Pharmaceuticals PLC (JAZZ) trades at a EV/Sales of 3.7×. Over the past ten years it has ranged from 2.2× (May 2025) to 10.2× (March 2015); the current reading is higher than 35% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.1× 18.02%
FY2024 2.6× (16.57%)
FY2023 3.2× (20.89%)
FY2022 4.0× (5.36%)
FY2021 4.2× 8.97%
FY2020 3.9× (6.95%)
FY2019 4.2× (4.06%)
FY2018 4.3× (23.86%)
FY2017 5.7× 1.61%
FY2016 5.6× (15.61%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 3.7× (0.73%)
Jun 2026 3.8× 18.22%
Mar 2026 3.2× 2.65%
Dec 2025 3.1× 14.37%
43 more quarters

Against its own ten years

Low 2.2× High 10.2×
Ten-year median 4.2×
Current reading's percentile 38

EV/Sales against peers

Company EV/Sales
JAZZ Jazz Pharmaceuticals PLC 3.7×
BMRN BioMarin Pharmaceutical Inc. compare 3.9×
EXEL Exelixis, Inc. compare 6.5×
HALO Halozyme Therapeutics, Inc. compare 9.0×
TECH Bio-Techne Corp compare 9.3×
ASND Ascendis Pharma A/S compare 13.1×
BBIO BridgeBio Pharma, Inc. compare 15.9×
KYMR Kymera Therapeutics, Inc. compare 111×
SMMT Summit Therapeutics PLC compare 15,046×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on JAZZ